The role of platelets in cancer: from their influence on tumor progression to their potential use in liquid biopsy
Por:
Morales-Pacheco M., Valenzuela-Mayen M., Gonzalez-Alatriste A.M., Mendoza-Almanza G., Cortés-Ramírez S.A., Losada-García A., Rodríguez-Martínez G., González-Ramírez I., Maldonado-Lagunas V., Vazquez-Santillan K., González-Covarrubias V., Pérez-Plasencia C., Rodríguez-Dorantes M.
Publicada:
1 ene 2025
Resumen:
Platelets, anucleate blood cells essential for hemostasis, are increasingly recognized for their role in cancer, challenging the traditional notion of their sole involvement in blood coagulation. It has been demonstrated that platelets establish bidirectional communication with tumor cells, contributing to tumor progression and metastasis through diverse molecular mechanisms such as modulation of proliferation, angiogenesis, epithelial-mesenchymal transition, resistance to anoikis, immune evasion, extravasation, chemoresistance, among other processes. Reciprocally, cancer significantly alters platelets in their count and composition, including mRNA, non-coding RNA, proteins, and lipids, product of both internal synthesis and the uptake of tumor-derived molecules. This phenomenon gives rise to tumor-educated platelets (TEPs), which are emerging as promising tools for the development of liquid biopsies. In this review, we provide a detailed overview of the dynamic roles of platelets in tumor development and progression as well as their use in diagnosis and prognosis. We also provide our view on current limitations, challenges and future research areas, including the need to design more efficient strategies for their isolation and analysis, as well as the validation of their sensitivity and specificity through large-scale and rigorous clinical trials. This research will not only enable the evaluation of their clinical viability but could also open new opportunities to enhance diagnostic accuracy and develop personalized treatments in oncology. © The Author(s) 2025.
Filiaciones:
Morales-Pacheco M.:
Laboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City, 14610, Mexico
Valenzuela-Mayen M.:
Laboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City, 14610, Mexico
Gonzalez-Alatriste A.M.:
Laboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City, 14610, Mexico
Mendoza-Almanza G.:
Laboratorio de Epigenética, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City, 14610, Mexico
Cortés-Ramírez S.A.:
Department of Pharmacology and Toxicology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, 72205, AR, United States
Losada-García A.:
Department of Pharmacology and Toxicology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, 72205, AR, United States
Rodríguez-Martínez G.:
Laboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City, 14610, Mexico
Laboratorio de Investigación en Patógenos Respiratorios y Producción de Biológicos, Hospital Infantil de México Federico Gómez, Mexico City, 14610, Mexico
González-Ramírez I.:
Departamento de Atención a La Salud, Universidad Autónoma Metropolitana Xochimilco, Mexico City, 14610, Mexico
Maldonado-Lagunas V.:
Laboratorio de Epigenética, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City, 14610, Mexico
Vazquez-Santillan K.:
Laboratorio de Innovación en Medicina de Precisión, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City, 14610, Mexico
González-Covarrubias V.:
Laboratorio de Farmacogenómica, Instituto Nacional de Medicina Genómica, Secretaría de Salud, Mexico City, 14610, Mexico
Pérez-Plasencia C.:
Laboratorio de Genómica, FES-Iztacala, Universidad Nacional Autónoma de México (UNAM), Iztacala, Tlalnepantla, 54090, Mexico
Rodríguez-Dorantes M.:
Laboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Mexico City, 14610, Mexico
gold, All Open Access; Gold Open Access
|